BridgeBio Pharma Announces $250 Mln PIPE Financing

September 25, 2023 — 09:10 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - BridgeBio Pharma, Inc. (BBIO), a company focused on genetic diseases and cancers, said on Friday that it has inked a deal with certain investors to issue and sell its 9.167 million shares at September 22 closing price of $27.27 per share through a private investment in public equity or PIPE financing.

Neil Kumar, CEO of BridgeBio, said: "Their support will help us fund our future operations, including the launch of acoramidis and our upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1, and will allow us to pursue additional less dilutive financing options to optimize our cost of capital…"

The drug maker expects gross proceeds of around $250 million from the transaction, which is scheduled to conclude on September 27.

The PIPE financing was led by Qatar Investment Authority, with the participation of investment management firms, institutional investors, and existing investors.

BridgeBio noted that it also continues to explore additional strategic options to fund the business.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

BridgeBio Pharma Announces $250 Mln PIPE Financing

Tags

Latest Articles